Accordingly, the sensitivity of PSAP (96.5%) and PSA (99.8%) were slightly higher in previous studies of our group analyzing large consecutive prostate cancer cohorts including much higher proportions of Gleason 3 + 3 and 3 + 4 cancer than in the current set of tumors. This evidence concerns the gene PSAP and prostate carcinoma.